{"id":3811,"date":"2026-10-21T09:00:00","date_gmt":"2026-10-21T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3811"},"modified":"2026-10-21T20:36:20","modified_gmt":"2026-10-22T00:36:20","slug":"asns-links-ube3a-loss-to-persistent-neuronal-stress-in-angelman-syndrome","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3811","title":{"rendered":"ASNS Links UBE3A Loss to Persistent Neuronal Stress in Angelman Syndrome"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Washington University investigators<\/p>\n

Event Type<\/strong><\/p>\n

Peer-Reviewed Preclinical Publication (Nature)<\/p>\n

Modality<\/strong><\/p>\n

Target discovery (downstream pathway; genetic rescue in mice)<\/p>\n

Asset<\/strong><\/p>\n

Not applicable (mechanism and target hypothesis)<\/p>\n

Target<\/strong><\/p>\n

ASNS (asparagine synthetase); UBE3A substrate pathway<\/p>\n

Disease Area<\/strong><\/p>\n

Angelman syndrome<\/p>\n

Summary<\/h4>\n

A Nature paper identifies asparagine synthetase as a UBE3A substrate and connects its accumulation to persistent neuronal stress signaling in Angelman syndrome. Genetic reduction of ASNS rescued several mouse phenotypes, adding a potential downstream intervention point beyond UBE3A reactivation.<\/p>\n

The team used gain- and loss-of-function UBE3A genetics, unbiased proteomics and mouse experiments. Elevated ASNS activated a stress pathway associated with reduced neuronal protein synthesis; genetically lowering ASNS restored protein synthesis, brain growth and multiple behavioral measures in model mice. The article was published online 21 October 2026 and is peer-reviewed. Human therapeutic dosing, delivery and safety are untested.<\/p>\n

Deep Analysis<\/h4>\n

UBE3A is an E3 ubiquitin ligase, so defining a disease-relevant substrate offers a direct chain from gene loss to cellular phenotype. ASNS reduction provides a second therapeutic hypothesis if reactivating the silent paternal UBE3A allele proves incomplete or hard to distribute across the brain. The genetic rescue is stronger than a correlative proteomics hit.<\/p>\n

The alternative is that lifelong germline ASNS reduction in mice does not approximate a postnatal drug or RNA therapy in children. ASNS is required for amino-acid metabolism, and systemic inhibition could harm developing tissues. Brain exposure, cell-type specificity, treatment timing, seizure effects and dose-dependent reversibility must be demonstrated. A clear falsifier would be failure of post-symptom, partial ASNS reduction to improve function without metabolic toxicity.<\/p>\n

Company and Product Background<\/h4>\n

Angelman syndrome is a neurodevelopmental disorder caused by loss of maternal neuronal UBE3A expression. UBE3A marks substrates for degradation. ASNS synthesizes asparagine, and excess neuronal ASNS was linked here to integrated-stress signaling and suppressed protein synthesis.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Fact:<\/strong> UBE3A\u2013ASNS mechanism and mouse genetic rescue in a peer-reviewed Nature article.<\/li>\n
  • Inference:<\/strong> ASNS is a candidate downstream target, with no clinical proof of benefit.<\/li>\n
  • Upgrade:<\/strong> postnatal, brain-directed ASNS reduction with functional rescue and safe metabolite profiles.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: the work broadens the Angelman target map but does not establish a treatment. The timing and safety of partial ASNS suppression will determine whether the mechanism can compete with UBE3A-restoration strategies.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: Positive, preclinical. Confidence in Facts: High. Confidence in Interpretation: Moderate\u2013Low. The direction score describes the evidence at this stage. It does not imply clinical approval, treatment readiness or commercial outcome.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A Nature paper identifies asparagine synthetase as a UBE3A substrate and connects its accumulation to persistent neuronal stress signaling in Angelman syndrome. Genetic reduction of ASNS rescued several mouse phenotypes, adding a potential downstream…<\/p>\n","protected":false},"author":1,"featured_media":3827,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[217,1132,1133,553,1131],"class_list":["post-3811","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-angelman-syndrome","tag-asns","tag-nature","tag-ube3a","tag-washington-university"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3811"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3811\/revisions"}],"predecessor-version":[{"id":3830,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3811\/revisions\/3830"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3827"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}